首页> 外文期刊>The Journal of pediatrics >Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States
【24h】

Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States

机译:利用行政数据监测全美42家独立儿童医院的2875名患者使用利妥昔单抗的情况

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To describe the pharmacoepidemiology of rituximab use in children and to estimate the frequency of infectious events within a 1-year period after rituximab exposure. Study design This is a retrospective cohort study of patients who received rituximab at 1 of 42 children's hospitals contributing data to the Pediatric Health Information System between January 1999 and June 2011. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) discharge diagnosis codes were analyzed to categorize underlying diseases (hematologic malignancies, primary immunodeficiencies, autoimmune diseases, and transplant recipients) and to estimate inpatient infectious complication rates within each category. Results A total of 2875 patients with 4639 rituximab admissions were identified. The median age at index admission was 11 years (IQR, 5-15 years). The rate of rituximab admissions increased from 3 to 185 per 100 000 admissions per year over the study interval. During the 1-year follow-up period, 463 patients (16%) died. Infectious events were assessed in 2246 of the rituximab-exposed patients; 6.1% were diagnosed with sepsis and 2.0% with septic shock. The frequency of sepsis ranged from 2.4% in patients with autoimmune diseases to 12.2% in those with primary immunodeficiencies. Three patients were assigned an ICD-9-CM discharge diagnosis code for Pneumocystis joroveci pneumonia, 1 patient was assigned an ICD-9-CM discharge diagnosis code for hepatitis B, and 1 patient was assigned an ICD-9-CM discharge diagnosis code for progressive multifocal leukoencephalopathy. Conclusion The use of rituximab has increased significantly in children with a variety of underlying diseases. Based on ICD-9-CM code data, the rates of sepsis and other life-threatening infections after rituximab exposure vary depending on the underlying condition. Based on surveillance of infection using ICD-9-CM diagnosis codes, the rates of opportunistic infections appear to be low.
机译:目的描述儿童使用利妥昔单抗的药物流行病学,并估计利妥昔单抗暴露后1年内的感染事件发生频率。研究设计这是一项回顾性队列研究,研究对象是1999年1月至2011年6月在42家儿童医院中的1家接受利妥昔单抗治疗的患者,这些数据为儿科健康信息系统提供了数据。国际疾病分类,第9次修订,临床修改(ICD-9-CM )对出院诊断代码进行了分析,以对基础疾病(血液系统恶性肿瘤,原发性免疫缺陷,自身免疫性疾病和移植受者)进行分类,并估计每个类别中的住院感染并发症发生率。结果共鉴定出2875例接受4639例利妥昔单抗治疗的患者。入院时的中位年龄为11岁(IQR,5-15岁)。在研究间隔中,每年每10万例接受接受利妥昔单抗治疗的人数从3人增加到185人。在1年的随访期内,有463例患者(16%)死亡。在2246名接受利妥昔单抗治疗的患者中评估了感染事件。 6.1%被诊断为败血症,2.0%被诊断为败血性休克。败血症的发生率范围从自身免疫性疾病患者的2.4%到原发性免疫缺陷患者的12.2%。 3例患者被指定为ICD-9-CM出院诊断为克氏肺炎性肺炎,1例患者被分配为ICD-9-CM出院诊断为乙型肝炎,1例患者被分配为ICD-9-CM出院诊断为进行性多灶性白质脑病。结论在患有多种潜在疾病的儿童中,利妥昔单抗的使用已显着增加。根据ICD-9-CM代码数据,利妥昔单抗暴露后脓毒症和其他威胁生命的感染的发生率会因基础情况而异。根据使用ICD-9-CM诊断代码进行的感染监测,机会性感染率似乎很低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号